Compare Enveric Biosciences Inc (ENVB) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kinross Gold Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Kinross Gold Corporation trades at $23.81 (market cap $27.62B). The key difference: Kinross Gold Corporation is far larger — about 4061.8× Enveric Biosciences Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Kinross Gold Corporation for 53 Days on average.
| ENVB | KGC | |
|---|---|---|
Market Cap | $6.80M | $27.62B |
Volume | 64,867 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $38.06 |
52-Week Low | $1.27 | $22.47 |
Typical Hold Time | 14 Days | 53 Days |
Enterprise Value | -$1.49M | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
KGC trades at $23.18, down 2.65% on the day, amid bearish technical signals and recent negative news. The stock shows strong fundamentals with a P/E of 8.87, net income margin of 37.52%, and robust cash flow growth, but faces headwinds from production guidance cuts and legal investigations. Recent earnings have consistently beaten expectations, with Q3 2026 results pending.
Outlook is mixed: valuation metrics and cash flow support upside to the $38.80 consensus target, but near-term risks from operational setbacks and legal overhangs may pressure the stock. Investors should weigh strong profitability against execution risks and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
